EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The burden of the coronavirus disease 2019 virus infection in Burkina Faso: Results from a World Health Organization UNITY population‐based, age‐stratified sero‐epidemiological investigation

Samiratou Ouedraogo iD, Isidore Tiandiogo Traoré, Dramane Kania, Nongodo Firmin Kaboré, Ariane Mamguem Kamga, Hermann Badolo, Mimbouré Yara, Guillaume Sanou, Amariane Koné, Samdapawindé Thérèse Kagoné, Esperance Ouédraogo, Blahima Konaté und 9 weitere

Influenza and Other Respiratory Viruses · 2023

DOI: 10.1111/irv.13216 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2023. Verfasst von Samiratou Ouedraogo und 20 weiteren Autor:innen. Beteiligte Einrichtung: Observatoire national de la santé de la population (ONSP) Institut National de Santé Publique (INSP) Ouagadougou Burkina Faso. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ANRS (France Recherche Nord&Sud Sida-HIV Hépatites), Canadian Institutes of Health Research (CIHR), Institut National de Santé Publique du Québec (INSPQ).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aimed to estimate the anti‐SARS‐CoV‐2 antibody seroprevalence in the general population of Bobo‐Dioulasso and Ouagadougou (Burkina Faso).

Methods

We collected from March to April 2021 blood samples from randomly selected residents in both main cities based on the World Health Organization (WHO) sero‐epidemiological investigations protocols and tested them with WANTAI SARS‐CoV‐2 total antibodies enzyme‐linked immunosorbent assay (ELISA) kits intended for qualitative assessment. We also recorded participants' socio‐demographic and clinical characteristics and information on exposure to SARS‐CoV‐2. Data were analysed with descriptive and comparative statistics.

Results

We tested 5240 blood samples collected between 03 March and 16 April 2021. The overall test‐adjusted seroprevalence for SARS‐CoV‐2 antibodies was (67.8% [95% CI 65.9–70.2]) ( N = 3553/3982). Seroprevalence was highest among participants aged 15–18 years old (74.2% [95% CI 70.5–77.5]) ( N = 465/627), compared with those aged 10–14 years old (62.6% [95% CI 58.7–66.4]) ( N = 395/631), or those over 18 (67.6% [95% CI 66.2–69.1]) ( N = 2693/3982). Approximately 71.0% (601/860) of participants aged 10–18 years old who tested positive for SARS‐CoV‐2 antibodies experienced no clinical COVID‐19 symptoms in the weeks before the survey, compared with 39.3% (1059/2693) among those aged over 18 years old.

Conclusion

This study reports the results of the first known large serological survey in the general population of Burkina Faso. It shows high circulation of SARS‐CoV‐2 in the two cities and a high proportion of asymptomatic adolescents. Further studies are needed to identify the SARS‐CoV‐2 variants and to elucidate the factors protecting some infected individuals from developing clinical COVID‐19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19AdolescentHumansAdultMiddle AgedChildSeroepidemiologic StudiesBurkina FasoSurveys and QuestionnairesAntibodies, Viral

Stichwörter der Autor:innen

Burkina FasoCOVID-19SARS-CoV-2WHO UNITY studyinfectious diseasepopulation-based seroprevalence

Substanzen

Antibodies, Viral

Autor:innen und Institutionen

  • Observatoire national de la santé de la population (ONSP) Institut National de Santé Publique (INSP) Ouagadougou Burkina Faso.
  • Institut National de Santé Publique du Québec (INSPQ) Montreal Quebec Canada.
  • The Department of Epidemiology, Biostatistics and Occupational Health, Faculty of Medicine McGill University Montreal Quebec Canada.
  • Centre MURAZ, Institut National de Santé Publique Bobo-Dioulasso Burkina Faso.
  • Institut Supérieur des Sciences de la Santé (INSSA) Université Nazi Boni Bobo-Dioulasso Burkina Faso.
  • Epidemiology and Quality of Life Research Unit, INSERM U1231 Georges Francois Leclerc Centre-UNICANCER Dijon France.

ORCID-Profile: Samiratou Ouedraogo

Förderung

  • ANRS (France Recherche Nord&Sud Sida-HIV Hépatites)
  • Canadian Institutes of Health Research (CIHR)
  • Institut National de Santé Publique du Québec (INSPQ)
  • Department of Epidemiology, Biostatistics and Occupational Health, Faculty of Medicine, McGill University
  • Agence Nationale de Recherches sur le Sida et les Hépatites Virales

Zitieren

APA

Ouedraogo, S., Traoré, I. T., Kania, D., Kaboré, N. F., Mamguem Kamga, A., Badolo, H., Yara, M., Sanou, G., Koné, A., Kagoné, S. T., Ouédraogo, E., Konaté, B., Médah, R., de Rekeneire, N., Poda, A., Diendere, A. E., Ouédraogo, B., Billa, O., Paradis, G., …, & Dabakuyo-Yonli, T. S. (2023). The burden of the coronavirus disease 2019 virus infection in Burkina Faso: Results from a World Health Organization UNITY population‐based, age‐stratified sero‐epidemiological investigation. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13216

Vancouver

Ouedraogo S, Traoré IT, Kania D, Kaboré NF, Mamguem Kamga A, Badolo H, et al. The burden of the coronavirus disease 2019 virus infection in Burkina Faso: Results from a World Health Organization UNITY population‐based, age‐stratified sero‐epidemiological investigation. Influenza and Other Respiratory Viruses. 2023. doi:10.1111/irv.13216

BibTeX
@article{Ouedraogo2023,
  author = {Ouedraogo, Samiratou and Traoré, Isidore Tiandiogo and Kania, Dramane and Kaboré, Nongodo Firmin and Mamguem Kamga, Ariane and Badolo, Hermann and Yara, Mimbouré and Sanou, Guillaume and Koné, Amariane and Kagoné, Samdapawindé Thérèse and Ouédraogo, Esperance and Konaté, Blahima and Médah, Rachel and de Rekeneire, Nathalie and Poda, Armel and Diendere, Arnaud Eric and Ouédraogo, Boukary and Billa, Oumar and Paradis, Gilles and Tinto, Halidou and Dabakuyo-Yonli, Tienhan Sandrine},
  title = {The burden of the coronavirus disease 2019 virus infection in Burkina Faso: Results from a World Health Organization UNITY population‐based, age‐stratified sero‐epidemiological investigation},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2023},
  doi = {10.1111/irv.13216}
}
Kostenlos starten →